<DOC>
	<DOCNO>NCT01050660</DOCNO>
	<brief_summary>The goal study determine parenteral nutrition-associated cholestasis ( PNAC ) relate amount parenteral ( intravenous ) fat administer premature baby full enteral nutrition achieve .</brief_summary>
	<brief_title>Low Dose Parenteral Fat Prevention Parenteral Nutrition Associated Cholestasis Preterm Neonates</brief_title>
	<detailed_description>In neonatal intensive care unit , parenteral nutrition widely use provide protein , energy , vitamins mineral infant accept enteral feed . Intravenous fat emulsion important component parenteral nutrition important caloric supply brings , also essential fatty acid ( linoleic linolenic acid ) provide . Because intravenous fat emulsion supply essential fatty acid , least enteral feed establish , minimum fat administer least 0.25g/kg /day preterm baby 0.1g/kg/day term infant ( Lee EJ , 1993 ) . The maximal dose intravenous fat safe administer difficult determine . Although large preterm infant intravenous fat tolerate well base measurement serum triglyceride , still question regard tolerance extremely low birth weight infant . Parenteral nutrition associate development liver disease-parenteral nutrition associate liver disease ( PNALD ) . PNALD range cholestasis transient elevation liver enzymes severe form include fibrosis , liver cirrhosis hepatic failure . Cholestasis , define hyperbilirubinemia direct bilirubin 2 mg/dL 15 % total bilirubin , hepatocellular injury liver manifest administration parenteral nutrition least two week . The mechanism liver injury occur unknown probably multifactorial . Risk factor associate development PNAC include : prematurity , low birth weight , absence enteral feed , bacterial sepsis , necrotizing enterocolitis , prolong use parenteral nutrition , multiple surgical procedure gastro-intestinal tract . In addition , many nutrient contain parenteral nutrition , link development cholestasis . Specific factor associate intravenous fat emulsion relate PNAC include : phytosterols , rate administration intravenous emulsion , total amount fat administer toxic metabolites intravenous fat emulsion . The total amount lipid find risk factor cholestasis child long-term parenteral nutrition decrease amount fat recommend prevention hepatic complication ( Colomb V , 2000 ) . In adult population parenteral lipid intake less 1gr/kg body weight decrease risk cholestasis parenteral nutrition treat patient ( Cavicchi , 2000 ) . Current Nutritional Management VLBW infant NBSCU : The administration parenteral nutrition preterm baby gestational age less equal 29 week ' standard practice NBSCU infant receive full enteral nutrition . Fat , integral part intravenous alimentation , start first day life dose 0.5 grams/kg/day 20 % fat emulsion ( eg , Lyposyn II , Abbott Laboratories Chicago , IL ) . The amount fat gradually increase 0.5-1 grams/kg/day total amount 3 grams/kg/day tolerate . The tolerance check measure serum triglyceride level morning 3 grams/kg/day reach first time serum triglyceride level ≤200 mg/dl accept infant ≤52 week postmenstrual age . If serum triglyceride level &gt; 200 mg/dL , intravenous fat emulsion reduce 24 hour , triglyceride level check ensure drop 200 mg/dL . The fat emulsion restart 1-1.5 grams/kg/day serum triglyceride level monitor slowly increase . Enteral nutrition start initially minimal enteral feeding , also call non-nutritive feeding , usually 48±12 hour age 12 ml/kg/day . The feeding advance tolerated goal reach full enteral nutrition ( &gt; 120 ml/kg/day ) 14-21days life . As enteral volume reach 1/3 , 1/2 , 2/3 total daily fluid volume , rate administration lipid emulsion decrease step ( ie , 2 grams/kg/day 1.5 1.0 ) , intravenous fat emulsion stop . As part standard NBSCU management guideline screen liver function consist measure serum direct bilirubin level baby TPN 10 day two week biweekly , PN continue . In addition , direct bilirubin level great 2.5mg/dL , liver enzymes check . Study Procedure : All preterm baby gestational age less equal 29 week ' bear YNHH receive intravenous fat emulsion part nutrition management eligible participate study . The parent baby approach first 24 hour life , regard possible participation study . After informed consent obtain , subject randomize YNHH Investigator pharmacy one two group : intervention ( restrict intravenous fat intake ) control ( standard intravenous fat intake ) . Therefore , purpose study determine PNAC related amount parenteral fat administer premature baby full enteral nutrition reach .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<mesh_term>Fat Emulsions , Intravenous</mesh_term>
	<criteria>Preterm infant less equal 29 week ' gestation Age le 48 hour Congenital intrauterine infection , know associate liver involvement cholestasis Known structural liver abnormality associate cholestasis Known genetic disorder : trisomy 21 , trisomy 13 trisomy 18 Inborn error metabolism Infants meet criterion terminal illness ( eg , pH &lt; 6.8 &gt; 2 hour ) Inability obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Parenteral nutrition associate liver disease</keyword>
	<keyword>Direct bilirubin</keyword>
	<keyword>Intravenous fat emulsion</keyword>
	<keyword>Very low birth weight infant</keyword>
	<keyword>PNAC</keyword>
</DOC>